Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Dr. Tomas  Navratil Ph.D.

Chief Development Officer

Ms. Diana A. Scherer

Vice President of Compliance & Deputy General Counsel

Mr. Chris M. Calcaterra

Executive Vice President of Global Commercial Operations

Ms. Jane E. Rady

Senior Vice President of Corporate Strategy & Business Development

Mr. Christopher William Lewis

Vice President of Investor Relations & Corporate Affairs

Ms. Michele M. Allegretto

Senior Vice President of Human Resources

Dr. Mory  Gharib Ph.D.

Co-Founder

Mr. Joseph E. Gilliam

President & Chief Operating Officer

Mr. Thomas William Burns

Chairman & Chief Executive Officer

Mr. Alex R. Thurman

Senior Vice President & Chief Financial Officer

Glaukos Corporation

Glaukos Corporation Management-Struktur

Informationen zum Management